Erratum to: Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study

@inproceedings{Mago2013ErratumTS,
  title={Erratum to: Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study},
  author={Rajnish Mago and Giovanna Forero and William M Greenberg and Carl P. Gommoll and Changzheng Chen},
  booktitle={Clinical drug investigation},
  year={2013}
}
BACKGROUND Levomilnacipran (1S, 2R-milnacipran) is a potent and selective serotonin (5-HT) and norepinephrine (noradrenaline) reuptake inhibitor approved for the treatment of major depressive disorder in adults. OBJECTIVE The objective of this study was to evaluate the longer-term safety and tolerability of levomilnacipran extended-release (ER). METHODS Patients who completed double-blind treatment/down-taper in one of three lead-in levomilnacipran ER studies were eligible for this 48-week… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
13 Citations
20 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 20 references

The efficacy and safety of levomilnacipran SR 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase III, randomized, double-blind, placebocontrolled study

  • G Asnis, A Bose, C Gommoll
  • J Clin Psychiatry
  • 2013
Highly Influential
4 Excerpts

W14. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran SR in patients with major depressive disorder [abstract]. Neuropsychopharmacol. 2012;38(Suppl 1):S322–3

  • A Sambunaris, A Bose, C Gommoll
  • 2012
Highly Influential
5 Excerpts

A randomized double-blind, placebo-controlled, flexible-dose study of levomilnacipran in patients with major depressive disorder

  • C Gommoll, A Bose, H Li
  • [poster]. 24th Annual US Psychiatric and Mental…
  • 2011
Highly Influential
5 Excerpts

Drug-drug interactions of levomilnacipran sustained release capsule with ketoconazole

  • L Chen, R Boinpally, N Gad
  • 2013
1 Excerpt

The efficacy and safety of levomilnacipran SR in the prevention of relapse in major depressive disorder: results from a phase III clinical trial

  • T Shiovitz, A Bose, WM Greenberg
  • [poster]. 25th Annual US Psychiatric and Mental…
  • 2012
1 Excerpt

W 14 . A phase III , double - blind , placebo - controlled , flexible - dose study of levo - milnacipran SR in patients with major depressive disorder [ abstract ]

  • A Sambunaris, A Bose, C Gommoll
  • Neuropsychopharmacol
  • 2012

Similar Papers

Loading similar papers…